Rems-Murr-Kliniken

Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome (2022) Georgi JA, Stasik S, Zukunft S, Hartwig M, Roellig C, Oelschlaegel U, Krug U, et al. Conference contribution In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial (2022) Stelljes M, Middeke JM, Bug G, Wagner EM, Mueller LP, Christoph S, Krause S, et al. Conference contribution Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations (2022) Eckardt JN, Stoelzel F, Kunadt D, Roellig C, Stasik S, Wagenfuehr L, Joehrens K, et al. Journal article Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study (2022) Middeke JM, Metzeler KH, Rollig C, Kramer M, Eckardt JN, Stasik S, Greif PA, et al. Journal article Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 (2021) Kayser S, Martinez-Cuadron D, Hanoun M, Stoelzel F, Gil C, Reinhardt HC, Aguiar E, et al. Conference contribution Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience (2021) Enssle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Conference contribution Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia (2021) Stasik S, Eckardt JN, Kramer M, Roellig C, Kraemer A, Scholl S, Hochhaus A, et al. Journal article A pre-infection laboratory score identifies cancer patients at risk for severe COVID-19: an analysis of the ADHOK coronavirus tumor registry (2021) Roesch R, Suedhoff T, Wendtner CM, Kullmann F, Schaich M, Kubin T, Mueller-Naendrup C, et al. Conference contribution Loss-of-function mutations of bcor are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia (2021) Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, et al. Journal article Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations–a registry based analysis (2021) Middeke JM, Teipel R, Roellig C, Stasik S, Zebisch A, Sill H, Kramer M, et al. Journal article